Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
BMC Cancer ; 20(1): 594, 2020 Jun 26.
Artículo en Inglés | MEDLINE | ID: mdl-32586289

RESUMEN

BACKGROUND: Patients with cancer have an increased risk of malnutrition which is associated with poor outcome. The Mini Nutritional Assessment (MNA®) is often used in older patients with cancer but its relation to outcome is not known. METHODS: Four databases were systematically searched for studies relating MNA-results with any reported outcome. Two reviewers screened titles/abstracts and full-texts, extracted data and rated the risk of bias (RoB) independently. RESULTS: We included 56 studies which varied widely in patient and study characteristics. In multivariable analyses, (risk of) malnutrition assessed by MNA significantly predicts a higher chance for mortality/poor overall survival (22/27 studies), shorter progression-free survival/time to progression (3/5 studies), treatment maintenance (5/8 studies) and (health-related) quality of life (2/2 studies), but not treatment toxicity/complications (1/7 studies) or functional status/decline in (1/3 studies). For other outcomes - length of hospital stay (2 studies), falls, fatigue and unplanned (hospital) admissions (1 study each) - no adjusted results were reported. RoB was rated as moderate to high. CONCLUSIONS: MNA®-result predicts mortality/survival, cancer progression, treatment maintenance and (health-related) quality of life and did not predict adverse treatment outcomes and functional status/ decline in patients with cancer. For other outcomes results are less clear. The moderate to high RoB calls for studies with better control of potential confounders.


Asunto(s)
Desnutrición/diagnóstico , Neoplasias/mortalidad , Estado Nutricional , Progresión de la Enfermedad , Humanos , Tiempo de Internación/estadística & datos numéricos , Desnutrición/etiología , Neoplasias/complicaciones , Neoplasias/terapia , Evaluación Nutricional , Admisión del Paciente/estadística & datos numéricos , Pronóstico , Supervivencia sin Progresión , Calidad de Vida , Factores de Riesgo , Factores de Tiempo
2.
J Perinatol ; 34(12): 906-8, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25058747

RESUMEN

OBJECTIVE: To evaluate whether Rh-positive preterm newborn infants born to Rh-negative mothers treated with prophylactic anti-D immunoglobulins exhibited signs of hemolytic reaction, including anemia and hyperbilirubinemia. STUDY DESIGN: Retrospective data were collected for 94 Rh-positive preterm newborns born at gestational age (GA) 28 to 34 weeks to 76 Rh-negative mothers and for matched controls. RESULT: We found 11.7% positive Coombs' tests among infants in the study group and slightly higher bilirubin levels at birth and on the following 3 days. No differences were recorded between the study and the control groups for hematocrit levels throughout hospitalization, maximal bilirubin level, phototherapy treatment or the need for blood transfusion. CONCLUSION: Among preterm Rh-positive newborn infants born to Rh-negative mothers, there appears to be no evidence of significant hemolytic reaction derived from placental anti-D transfer. Further prospective studies are needed to confirm these findings in order to support anti-D administration close to preterm birth.


Asunto(s)
Hemólisis/efectos de los fármacos , Recien Nacido Prematuro , Globulina Inmune rho(D)/uso terapéutico , Adulto , Bilirrubina/sangre , Prueba de Coombs , Eritroblastosis Fetal/prevención & control , Femenino , Hematócrito , Humanos , Recién Nacido , Modelos Logísticos , Masculino , Embarazo , Resultado del Embarazo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA